Analysts' Actions: BAC, JCP, NTAP

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Bank of America ( BAC) was upgraded at Guggenheim from Neutral to Buy. $11 price target. Expect favorable first-quarter earnings, Guggenheim said.

Ball ( BLL) was initiated with a Hold rating at Keybanc. The stock is trading above its historical average valuation, Keybanc said.

Fidelity National ( FIS)was initiated with a Market Perform rating at Wells Fargo. Valuation call.

Endocyte ( ECYT) was initiated with a Sell rating at TheStreet Ratings.

Gamestop ( GME) was downgraded at Needham from Buy to Hold. Slower retail sales could hurt the company, Needham said.

JC Penney ( JCP) was initiated with a Neutral rating at UBS. $36 price target. Cost cuts should limit stock downside in the meantime, UBS said.

Nordstrom ( JWN) was initiated with a Buy rating at UBS. $63 price target. Hidden value supports a premium valuation, UBS said.

Kohl's ( KSS) was initiated with a Neutral rating at UBS. $53 price target. Growing pains still hurt, but capital strategy could change that, UBS said.

Macy's ( M) was initiated with a Neutral rating at UBS. $43 price target. SSS outperformance should continue, UBS said.

NetApp ( NTAP) was downgraded at FBN Securities from Outperform to Sector Perform. $45 price target. Channel checks suggest weaker sales, FBN said.

Pan American Silver Corp. ( PAAS) was downgraded to Hold at TheStreet Ratings.

Saks ( SKS) was initiated with a Neutral rating at UBS. $12 price target. Fixing legacy real estate issues key to driving fundamentals higher, UBS said.

Silicon Labs ( SLAB) was upgraded at Wunderlich from Hold to Buy. $50 price target. Selloff has created an attractive entry point, Wunderlich said.

Sterling Financial ( STSA) was initiated with a Market Perform rating at Keefe, Bruyette & Woods. Valuation call, based on a $19 price target, Keefe, Bruyette & Woods said.

Viropharma ( VPHM) was downgraded to Hold at Brean Murray. Vancocin will soon face heavy generic competition, Brean Murray said.

Yelp ( YELP) was initiated with a Neutral rating at Citigroup. $28 price target. Very robust valuation offsets significant market opportunity, Citigroup said.

Yelp was initiated with a Neutral rating at Goldman Sachs. $26 price target. Business model is still in its early stages, Goldman said.

Yelp was initiated with a Perform rating at Oppenheimer. $23 price target. Key metrics have material upside, Oppenheimer said.

Stock Comments / EPS Changes

Alcoa ( AA) estimates were raised at UBS through 2013. Improved outlook in the mid/downstream sectors, UBS said. Neutral rating.

Apple ( AAPL) estimates, target were boosted at Sterne Agee. Shares are now seen reaching $750. Estimates were also increased, following channel checks, Sterne Agee. Buy rating.

Ball numbers were raised at Jefferies. Shares are now seen reaching $49. Estimates also raised on favorable rigids volume trends, Jefferies said. Buy rating.

Canadian Pacific Railway ( CP) numbers were raised at Jefferies. Shares are now seen reaching $72. Estimates were also raised on first-quarter guidance, Jefferies said. Hold rating.

Forest Labs ( FRX) numbers were cut at Credit Suisse. Shares are now seen reaching $44. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating.

First Solar ( FSLR) numbers were cut at UBS. Shares are now seen reaching $23. Estimates were also lowered as module business is affecting system value, UBS said. Neutral rating.

Las Vegas Sands ( LVS) numbers were increased at BMO Capital. Estimates were raised through 2013. Macau should continue to drive growth, BMO Capital said. Outperform rating and new $69 price target.

Priceline.com ( PCLN) numbers were raised at Benchmark. Shares are now seen reaching $840. Estimates were also increased, given better industry trends and emerging market growth, Benchmark said. Buy rating.

Qlik Technologies ( QLIK) price target was raised at Jefferies to $35. Survey suggests modest upside risk, Jefferies said. Buy rating.

VMware ( VMW) price target was raised at Jefferies to $100. Improved current year growth expectations, Jefferies said. Hold rating.

ViroPharma Incorporated ( VPHM) numbers were lowered at Jefferies. Shares are now seen reaching $33. Estimates were also lowered on FDA approval of generic Vancocin, Jefferies said. Buy rating.

ViroPharma Incorporated numbers were lowered at Oppenheimer. Shares are now seen reaching $27. Estimates were also lowered on denial of Citizen's Petition related to Vancocin, Oppenheimer said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Citigroup Gives CEO Corbat 48% Pay Raise as Profitability Misses Goal

Citigroup Gives CEO Corbat 48% Pay Raise as Profitability Misses Goal

Worst-In-Class Goldman Sachs CEO Blankfein Gets 9% Pay Raise

Worst-In-Class Goldman Sachs CEO Blankfein Gets 9% Pay Raise

Why Bank of America and Goldman Sachs Shares Are Perfect Inflation Hedges

Why Bank of America and Goldman Sachs Shares Are Perfect Inflation Hedges

Stock Market Volatility Leads to Frightened Investors: Bank of America Survey

Stock Market Volatility Leads to Frightened Investors: Bank of America Survey

JPMorgan, Bank Stocks Have Room to Run Higher in Slow-Motion Economy

JPMorgan, Bank Stocks Have Room to Run Higher in Slow-Motion Economy